Company intelligence / Profile preview

CD28

Würzburg, Bavaria, Germany

Ownership: Private
Development stage: Other

Overview

CD28 Therapeutics is a biotechnology company focused on developing novel immunotherapies that target the CD28 co-stimulatory pathway. The company leverages deep expertise in T-cell biology to create antibodies designed to modulate immune responses for the treatment of autoimmune disorders and cancer. By specifically engaging the CD28 receptor, their candidates aim to either suppress overactive immune cells in inflammatory conditions or activate T-cells to combat tumors. The company is a successor entity in the field of CD28 research, building upon decades of scientific discovery regarding T-cell activation signals.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on CD28.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD28.

Explore the full profile